21:52 , Jul 12, 2018 |  BC Extra  |  Company News

Korea: Samsung Biologics violated accounting rules

Korea’s Securities and Futures Commission ruled Thursday that Samsung BioLogics Co. Ltd. (KSE:207940) violated accounting rules during its 2016 IPO and has requested dismissal of executives and referral of the case to prosecutors. The move...
18:07 , Jun 29, 2018 |  BC Week In Review  |  Company News

Biogen ups biosimilar JV stake

Biogen Inc. (NASDAQ:BIIB) exercised its option to increase ownership in Samsung Bioepis to about 49.9% from 5.4%. Samsung Bioepis is a biosimilars JV between Biogen and Samsung BioLogics Co. Ltd. (KSE:207940), which will receive $700...
21:43 , Jun 28, 2018 |  BC Extra  |  Company News

Biogen ups biosimilar JV stake

Biogen Inc. (NASDAQ:BIIB) exercised its option to increase ownership in Samsung Bioepis to about 49.9% from 5.4%. Samsung Bioepis is a biosimilars JV between Biogen and Samsung BioLogics Co. Ltd. (KSE:207940), which will receive $700...
19:01 , Jun 1, 2018 |  BC Week In Review  |  Company News

Samsung JV may not be in Biogen's long term plans

Biogen Inc. (NASDAQ:BIIB) management said staying in its Samsung Bioepis JV with Samsung BioLogics Co. Ltd. (KSE:207940) may not be in its long-term plans. The comments about the biosimilars JV formed in 2012 were made...
21:30 , May 30, 2018 |  BC Extra  |  Company News

Biogen hints at Samsung Bioepis JV exit

Biogen Inc. (NASDAQ:BIIB) management said staying in its Samsung Bioepis JV with Samsung BioLogics Co. Ltd. (KSE:207940) may not be in its long-term plans. The comments about the biosimilars JV formed in 2012 were made...
20:00 , May 18, 2018 |  BC Week In Review  |  Company News

Biogen intends to increase stake in Samsung Bioepis

Samsung BioLogics Co. Ltd. (KSE:207940) said it received a letter from partner Biogen Inc. (NASDAQ:BIIB) in which the biotech said it intends to exercise its option to increase its stake in Samsung Bioepis, a JV...
16:24 , May 4, 2018 |  BC Week In Review  |  Clinical News

CRL for Sandoz's biosimilar rituximab

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said it received a complete response letter from FDA for a BLA for GP2013, the company's biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). Sandoz said it is...
15:57 , May 4, 2018 |  BC Week In Review  |  Company News

Samsung BioLogics shares fall on audit concerns

Samsung BioLogics Co. Ltd. (KSE:207940) fell W84,000 (17%) to W404,000 on May 2 after the company received undisclosed details regarding the implementation of an audit by Korea's Financial Supervisory Service (FSS). The stock move translates...
18:15 , May 3, 2018 |  BC Extra  |  Company News

CRL for Sandoz's biosimilar rituximab

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said it received late Wednesday a complete response letter from FDA for a BLA for GP2013, the company's biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). Sandoz said...
21:26 , May 2, 2018 |  BC Extra  |  Company News

Samsung BioLogics shares fall on audit concerns

Samsung BioLogics Co. Ltd. (KSE:207940) fell W84,000 (17%) to W404,000 on Wednesday after the company received undisclosed details regarding the implementation of an audit by Korea's Financial Supervisory Service (FSS). The stock move translates to...